Summary of Key Points Core Viewpoint - Titan Pharmaceuticals, Inc. has completed a private placement of Series B Convertible Preferred Stock with Blue Harbour Asset Management for a total of $1,000,000, with a conversion price set at $3.00 per share [1]. Group 1: Private Placement Details - The private placement involved the sale of 100,000 shares of Preferred Stock to Blue Harbour for an aggregate purchase price of $1,000,000 [1]. - The shares sold in this transaction are not part of a public offering and have not been registered under the Securities Act of 1933, relying on Regulation S [3]. - Titan has entered into a registration rights agreement with Blue Harbour, which outlines certain registration rights upon the occurrence of specified events [3]. Group 2: Ownership Conversion Blocker - The Certificate of Designations for the Preferred Stock includes a beneficial ownership conversion "blocker" that limits Blue Harbour's ability to acquire more than 19.99% of the Company's outstanding common stock without shareholder approval [2]. Group 3: Financial Advisory - ARC Group Ltd. acted as the sole financial advisor to Titan Pharmaceuticals during this private placement [4].

As filed with the U.S. Securities and Exchange Commission on September 29, 2023 Registration No. 333-274331 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 WiSA Technologies, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 3674 30-1135279 (I.R.S. Employer Identif ...